Editas Medicine Reports Robust Preclinical Data for EDIT-401, Plans Human Trials by Year-End
EDIT sits 91% above its 52-week low of $1.485.
Summary
Editas Medicine announced robust preclinical data for its gene-editing candidate, EDIT-401, demonstrating significant reductions in LDL-C, Lp(a), and ApoB, alongside plans to initiate human clinical trials by late 2026.
Key Events · Product Development and Regulatory · EDIT
-
Robust Preclinical Efficacy
EDIT-401 achieved approximately 90% or greater mean reductions in LDL-cholesterol (LDL-C), lipoprotein(a) (Lp(a)), and apolipoprotein B (ApoB) in non-human primates with a single dose.
-
Positive Safety Profile
Preclinical studies, including an ongoing GLP toxicology study, demonstrated EDIT-401 was well-tolerated at the therapeutically relevant dose of 1.5 mg/kg, with no adverse clinical observations or notable liver enzyme elevations.
-
Clear Clinical Pathway Established
The company received positive pre-IND feedback from the FDA and plans to submit a Clinical Trial Notification (CTN) in Australia by mid-2026 to initiate a first-in-human clinical trial for EDIT-401 in patients with Heterozygous Familial Hypercholesterolemia (HeFH) later in 2026.
-
Near-Term Human Proof-of-Concept
Editas Medicine expects to have early in vivo human proof-of-concept data for EDIT-401 by the end of 2026, with topline data from Part 1 of the Phase 1/2 trial anticipated in 2027.
Analysis · EDIT · Life Sciences
Editas Medicine presented strong preclinical data for its lead gene-editing candidate, EDIT-401, showing significant reductions in key cardiovascular risk factors. This data, combined with positive FDA feedback and a clear plan to initiate human clinical trials by the end of 2026, substantially de-risks the program and provides a critical path forward for the company's pipeline. Achieving early human proof-of-concept data by year-end would be a major milestone for this gene-editing therapy.
How filings like this one have moved
In the 30 days to Aug 24, 2026, 37.5% of the 3362 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EDIT was trading at $2.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $270.2M. The 52-week trading range was $1.49 to $4.54. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.